The Role of ACT Score in Mepolizumab Discontinuation

CONCLUSION: In this real-world study, we find that high eosinophil count may not be adequate in screening which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.PMID:38064231 | DOI:10.1080/02770903.2023.2293067

Source: Journal of Asthma - December 8, 2023 Category: Respiratory Medicine Authors: Neha Solanki Brittany Beck Monica Labadia Kevin Smith Laura Peterson Stephanie King Sarah Micklewright Emily Pennington Sobia Farooq Peng Zhang Mark Aronica Joe Zein Sumita Khatri Suzy Comhair Serpil Erzurum Source Type: research